Association of ApaI and BsmI polymorphisms with vitiligo risk: A meta-analysis

Clinical and Experimental Dermatology

Volumn 40, Issue 7, 2015, Pages 794-803

  Li, L ^a   Wu, Y ^a   Cai, Y F ^a   Geng, L ^a   Gao, X H ^a   Chen, H D ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APAI PROTEIN; BSMI PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ENDODEOXYRIBONUCLEASE BSMI; GGGCCC-SPECIFIC TYPE II DEOXYRIBONUCLEASES; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ALLELE; ARTICLE; CHINA; CNKI DATABASE; COCHRANE LIBRARY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; MEDLINE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VITILIGO; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; RISK FACTOR;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; RISK FACTORS; VITILIGO;

EID: 84941741657     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12633     Document Type: Article

References (26)

1. Kruger C, Schallreuter KU,. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012; 51: 1206-12.
2. Zhang XJ, Chen JJ, Liu JB,. The genetic concept of vitiligo. J Dermatol Sci 2005; 39: 137-46.
3. Amano H, Abe M, Ishikawa O,. First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol 2008; 25: 262-4.
4. Parsad D, Kanwar AJ,. Topical vitamin D analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009; 22: 487-8.
5. Birlea S, Birlea M, Cimponeriu D, et al., Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Derm Venereol 2006; 86: 209-14.
6. Adorini L,. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005; 233: 115-24.
7. Kostner K, Denzer N, Muller CS, et al., The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009; 29: 3511-36.
8. Vandenbroucke JP, von Elm E, Altman DG, et al., Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007; 18: 805-35.
9. Zintzaras E, Ioannidis JP,. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-37.
10. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
11. Aydingoz IE, Bingul I, Dogru-Abbasoglu S, et al., Analysis of vitamin D receptor gene polymorphisms in vitiligo. Dermatology 2012; 224: 361-8.
12. Li K, Shi Q, Yang L, et al., The association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with generalized vitiligo. Br J Dermatol 2012; 167: 815-21.
13. Guo R, Hao YJ, Wang JX, et al., Investigation on association of VDR gene polymorphism with Hui and Han ethnic vitiligo patients in NingXia. Chin J Lab Diagn 2012; 16: 2223-6.
14. Sun Y, Han J, Wu RQ, et al., Vitamin D receptor gene Apa I, Bsm I, Fok I polymorphism in patients of vitiligo. Chin J Derm Venereol 2009; 23: 695-8.
15. Wei HP, Zhong YJ, Li XH,. VDR Apa I gene polymorphism with dysimmunity. China Health Ind 2013; 6: 135-6.
16. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, et al., Autoimmune aspects of depigmentation in vitiligo. J Invest Dermatol Symp Proc 2004; 9: 68-72.
17. Niepomniszcze H, Amad RH,. Skin disorders and thyroid diseases. J Endocrinol Invest 2001; 24: 628-38.
18. Weiss GR, Fehrenkamp SH, Tokaz LK, Sunderland MC,. Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4. Dermatology 1996; 192: 283-5.
19. Adorini L, Penna G,. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008; 4: 404-12.
20. Morrison NA, Yeoman R, Kelly PJ, Eisman JA,. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci USA 1992; 89: 6665-9.
21. Haussler MR, Whitfield GK, Haussler CA, et al., The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13: 325-49.
22. Rodriguez-Martin M, Garcia Bustinduy M, Saez Rodriguez M, Noda Cabrera A,. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 2009; 160: 409-14.
23. Arca E, Tastan HB, Erbil AH, et al., Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006; 33: 338-43.
24. Goldinger SM, Dummer R, Schmid P, et al., Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007; 21: 504-8.
25. Liu JL, Zhang SQ, Zeng HM,. ApaI, BsmI, FokI and TaqI polymorphisms in the vitamin D receptor (VDR) gene and the risk of psoriasis: a meta-analysis. J Eur Acad Dermatol Venereol 2013; 27: 739-46.
26. Mao S, Huang S,. Association between vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus: a meta-analysis. Rheumatol Int 2014; 34: 381-8.